مستويات MASP-2 المصليّة عند أطفال سوريين مصابين بابيضاض الدم اللمفاوي الحاد

Authors

  • جمانة الصالح
  • راغب حرب

Abstract

خلافاً للمناعة التلاؤمية ومكونات معينة من المناعة الخلقية، قليل ما هو معلوم عن وظيفة جملة المتممة في تعزيز وكبت السرطان. يُعتبر سبيل الليكتين لتفعيل المتممة جزءاً هاماً من المناعة الخلقية. إنه مكتنف بشكل رئيسي في طهاية وانحلال الممراضات وتوظيف الخلايا الالتهابية. تهدف دراستنا إلى تقييم العلاقة بين المستويات المصلية لبروتياز السيرين المشارك لليكتين الرابط للمانوز -2 (MASP-2) قبل وبعد المعالجة الكيميائية عند أطفال سوريين مصابين بابيضاض الدم اللمفاوي الحاد (ALL) acute lymphoblastic leukemia بهدف إيجاد علاقة تساعد في التنبؤ المبكر لاستجابة المرضى للمعالجة الكيميائية، حيث تمت الدراسة بين عامي 2013 و 2014 في مستشفى الأطفال الجامعي بدمشق وشملت 37 طفلاً مشاركاً مصاباً بابيضاض الدم اللمفاوي الحاد، حيث تم قياس مستويات بروتياز السيرين المشارك لليكتين الرابط للمانوز-2 (MASP-2) المصلية بطريقة الممتز المناعي المرتبط بالإنزيم (ELISA). فكانت النتيجة أن وُجِدَ أن مستويات MASP-2 المصليّة قد انخفضت بشكل ملحوظ بعد المعالجة الكيميائية عند الأطفال المصابين بابيضاض الدم اللمفاوي الحاد، وكذلك وُجِدَ علاقة ارتباط قوية بين مستويات الواسم قبل وبعد المعالجة. In contrast to adaptive immunity and to certain components of innate immunity, only little is known on the influence of the complement system on cancer suppression and promotion . The lectin pathway of complement activation is an important part of innate immunity. It is mainly involved in opsonisation and lysis of pathogens and in recruitment of inflammatory cells. Our study aimed to assess the relationship between MASP-2 serum levels before and after chemotherapy in Syrian children with acute lymphoblastic leukemia, aiming to find a relation, which serve in early forecast of patients response to chemotherapy, where the study has been done at Children University Hospital in damascus between 2013-2014. This study included 37 children diagnosed with acute lymphoblastic leukemia (ALL). The levels of Mannose-Binding Lectin-associated Serine Protease-2 (MASP-2) were determined by Enzyme Linked Immuno Sorbent Assay (ELISA). The result was that serum levels of MASP-2 was strongly reduced after chemotherapy in children with acute lymphoblastic leukemia, and a strong correlation between serum marker levels before and after chemotherapy was found.

Downloads

Published

2016-07-21

How to Cite

1.
الصالح ج, حرب ر. مستويات MASP-2 المصليّة عند أطفال سوريين مصابين بابيضاض الدم اللمفاوي الحاد. Tuj-hlth [Internet]. 2016Jul.21 [cited 2025Apr.18];37(3). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/1781

Issue

Vol. 37 No. 3 (2015): العلوم الصحية

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.